Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Hodgkin Disease trials

The registry lists 10 Hodgkin Disease studies with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor. 1 are open to participants now and 6 have results posted.

Early Phase 1 1Phase 1 4Phase 2 6No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
• Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in LymphomaCompletedNCT01665768Phase 2Results posted
• Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic CancersTerminatedNCT01135329Phase 2Results posted
• Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's LymphomaCompletedNCT00484874Phase 1/2Results posted
• Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's LymphomaTerminatedNCT00478062Phase 1/2Results posted
• Phase 2 Study of Rituximab-ABVD in Classical Hodgkin LymphomaCompletedNCT00369681Phase 2Results posted
• Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin LymphomaCompletedNCT00134082Phase 1/2Results posted
• Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin LymphomaTerminatedNCT01900496Phase 1
• 124I-FIAU Imaging in EBV and KSHV Associated CancersCompletedNCT00982449Not applicable
• Studying Fentanyl in Patients With CancerTerminatedNCT00899951